Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2017
Price : $35 *
At a glance
- Drugs Sonidegib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Aug 2015 Planned End Date changed from 1 Oct 2019 to 1 Sep 2020 as reported by ClinicalTrials.gov record.